| Date Filed | Type | Description |
| 05/12/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 05/02/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 04/27/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/17/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 04/05/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 04/03/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 02/28/2023 |
4
| Saba Capital Management, L.P. (10% Owner) has filed a Form 4 on Intelligent Medicine Acquisition Corp.|
Txns:
| Disposed/sold 2,170,581 shares
@ $10.34, valued at
$22.4M
|
|
| 02/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/09/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 02/03/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 02/03/2023 |
8-K
| Quarterly results |
| 01/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/19/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 01/04/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/07/2022 |
3/A
| Form 3/A - Initial statement of beneficial ownership of securities: [Amend] |
| 05/17/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/17/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 05/09/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 05/09/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 03/30/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/14/2022 |
SC 13G/A
| Saba Capital Management, L.P. reports a 6.8% stake in Intelligent Medicine Acquisition Corp |
| 02/11/2022 |
SC 13G/A
| Sculptor Capital LP reports a 4.3% stake in INTELLIGENT MEDICINE ACQUISITION CORP. |
| 02/11/2022 |
SC 13G
| Intelligent Medicine Sponsor LLC reports a 18.9% stake in Intelligent Medicine Acquisition Corp. |
| 02/08/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/27/2022 |
SC 13G/A
| HIGHBRIDGE CAPITAL MANAGEMENT LLC reports a 4.8% stake in Intelligent Medicine Acquisition Corp. |
| 12/23/2021 |
8-K
| Quarterly results |
| 12/20/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 11/19/2021 |
SC 13G
| HIGHBRIDGE CAPITAL MANAGEMENT LLC reports a 5.2% stake in Intelligent Medicine Acquisition Corp. |
| 11/15/2021 |
SC 13G
| Saba Capital Management, L.P. reports a 7.6% stake in Intelligent Medicine Acquisition Corp |
| 11/12/2021 |
SC 13G
| Sculptor Capital LP reports a 5.6% stake in INTELLIGENT MEDICINE ACQUISITION CORP. |
| 11/10/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...|
Docs:
|
"Underwriting Agreement, between the Company and Cantor Fitzgerald & Co. representative of the several underwriters",
"Amended and Restated Certificate of Incorporation",
"Warrant Agreement, between Continental Stock Transfer & Trust Company and the Company",
"Warrant Purchase Agreement, between the Company and the Intelligent Medicine Sponsor, LLC",
"Warrant Purchase Agreement, between the Company and Cantor Fitzgerald & Co",
"Investment Management Trust Account Agreement, between Continental Stock Transfer & Trust Company and the Company",
"Registration and Stockholder Rights Agreement, among the Company, Intelligent Medicine Sponsor, LLC and the other Holders (as defined therein) signatory thereto",
"Letter Agreement, among the Company, Intelligent Medicine Sponsor LLC and each of the initial stockholders, directors and officers of the Company",
"Form of Indemnification Agreement, between the Company and each of the officers and directors of the Company",
"Intelligent Medicine Acquisition Corp. Announces Pricing of $150,000,000 Initial Public Offering" |
|
| 11/08/2021 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
|